Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
15,137
Total Claims
$1.5M
Drug Cost
883
Beneficiaries
$1,686
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+90%
Opioid rate vs peers
4.2% vs 2.2% avg
+19%
Cost per patient vs peers
$1,686 vs $1,411 avg
+17%
Brand preference vs peers
12.4% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
4.2%
Opioid Rate
643
Opioid Claims
$18K
Opioid Cost
8.7%
Long-Acting Rate
Brand vs Generic
Brand: 1,864 claims · $1.2M
Generic: 13,186 claims · $293K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 90 | $155K |
| Apixaban | 82 | $86K |
| Empagliflozin | 82 | $86K |
| Fluticasone/Umeclidin/Vilanter | 69 | $78K |
| Rivaroxaban | 69 | $74K |
| Tirzepatide | 40 | $64K |
| Insulin Glargine,hum.Rec.Anlog | 48 | $58K |
| Dulaglutide | 23 | $45K |
| Mirabegron | 44 | $43K |
| Dapagliflozin Propanediol | 42 | $37K |
| Sitagliptin Phosphate | 23 | $32K |
| Semaglutide | 18 | $27K |
| Linagliptin | 16 | $27K |
| Insulin Lispro | 11 | $25K |
| Umeclidinium Brm/Vilanterol Tr | 25 | $25K |
Prescribing Profile
Patient Profile
75
Avg Age
66%
Female
1.50
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About